Skip to search formSkip to main contentSkip to account menu

GDC-0068

National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Use of Kinase Inhibitors to Illuminate Signaling Pathways in Breast Cancer
Currently, breast cancer is the most commonly diagnosed cancer and the second leading cause of cancer-related deaths among women… 
2017
2017
Asymmetric Synthesis of Ipatasertib
Significance: Ipatasertib (GDC-0068) is an Akt kinase inhibitor that that is of interest for the treatment of cancer. The… 
2016
2016
Abstract OT1-03-09: FAIRLANE: A phase II randomized, double-blind, study of the Akt inhibitor ipatasertib (Ipat, GDC-0068) in combination with paclitaxel (Pac) as neoadjuvant treatment for early…
Background: TNBC often exhibits activation of PI3K/Akt signaling, associated with loss of PTEN expression, low INPP4B expression… 
2015
2015
Long noncoding RNA AK 056155 involved in the development of Loeys-Dietz syndrome through AKT / PI 3 K signaling pathway
Loeys-Dietz syndrome (LDS) is an autosomal dominant genetic connective tissue disorder, and most of LDS patients will develop… 
2014
2014
Abstract NG01: Blockade of EGFR and HER3 enhances PI3K/Akt antitumor activity in triple negative breast cancer
Proceedings: AACR Annual Meeting 2014; April 5-9, 2014; San Diego, CA Triple negative breast cancer (TNBC) is clinically defined… 
2013
2013
Synthesis of Akt Inhibitor GDC-0068
Significance: Akt is a kinase that controls cellular processes by phosphorylating substrates involved in apoptosis, transcription… 
2012
2012
Combined Blockade of PI3K/AKT and EGFR/HER3 Enhances Anti-Tumor Activity in Triple Negative Breast Cancer
2012
2012
A Phase Ib Study of the Akt Inhibitor GDC-0068 with Docetaxel or mFOLFOX6 in Patients with Advanced Solid Tumors 3021
2012
2012
Phase Ib Dose Escalation Study of the Akt Inhibitor GDC-0068 with Docetaxel or mFOLFOX6 in Patients with Advanced Solid Tumors
J.C. Bendell,1 D. Roda,2 J. Mateo,3 A. Hollebecque,4 L. De Mattos-Arruda,5 R.D. Meng,6 S.J. Isakoff,7 L.R. Molife,3 A. Cervantes…